You are here

  • Home
  • Archive
  • Volume 78, Issue 3
  • Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Article info

Article menu
Download PDFPDF
Rheumatoid arthritis
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Authors

  • Kathrine Lederballe Grøn DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Elizabeth V Arkema Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Bente Glintborg DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Frank Mehnert Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark PubMed articlesGoogle scholar articles
  • Mikkel Østergaard DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Lene Dreyer Departments of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg, Denmark PubMed articlesGoogle scholar articles
  • Mette Nørgaard Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark PubMed articlesGoogle scholar articles
  • Niels Steen Krogh ZiteLab ApS, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • Johan Askling Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden PubMed articlesGoogle scholar articles
  • Merete Lund Hetland DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • The ARTIS Study Group
    Google scholar articles
  1. Correspondence to Dr Kathrine Lederballe Grøn, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; kathrine.l.groen{at}gmail.com
View Full Text

Citation

Grøn KL, Arkema EV, Glintborg B The ARTIS Study Group, et al
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden
Annals of the Rheumatic Diseases 2019;78:320-327.

Publication history

  • Received August 23, 2018
  • Revised November 8, 2018
  • Accepted November 26, 2018
  • First published January 5, 2019.
Online issue publication 
July 13, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.